ALNY Alnylam Pharmaceuticals, Inc. - Common Stock
O Alnylam Pharmaceuticals, Inc. - Common Stock Przegląd firmy z Wikipedii
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
Czytaj więcej
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
History
The company is a spin-off from the Max Planck Institute for Biophysical Chemistry. In 2002, Alnylam was founded by scientists Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, and Phillip Zamore, and by investors Christoph Westphal and John Kennedy Clarke; John Maraganore was the founding CEO. The company was named after Alnilam, a star in Orion's belt. The spelling was modified to make it unique. In 2003, the firm merged with the German pharmaceutical company, Ribopharma AG. The newly formed company also received $24.6 million in funding from private-equity firms. On February 27, 2004, Alnylam Pharmaceuticals filed for an IPO. The company raised $26 million and began trading as ALNY on the Nasdaq stock exchange.
In 2005, the company partnered with Medtronic to develop drug-device combinations to treat neurodegenerative disorders, and in 2006 with Biogen Idec to develop treatments of progressive multifocal leukoencephalopathy. In 2007, it entered into a nonexclusive alliance with Hoffmann-La Roche, in which Alnylam received $331 million in exchange for access to its technology platform. and also partnered with Ionis Pharmaceuticals to found the company Regulus Therapeutics, focused on microRNA therapeutics.
In 2009, the company formed alliances with Cubist Pharmaceuticals and Kyowa Hakko Kirin to market a drug targeted at respiratory syncytial virus. In 2010, it expanded its previous collaboration with Medtronic to include the CHDI Foundation in its Huntington's disease focused research. In 2011, it partnered with GlaxoSmithKline to develop RNAi technology enhancing vaccine production. The company entered into a 10-year alliance with Monsanto in 2012, to develop biotech solutions for the farming industry by developing natural molecules for crop protection. In 2012, it formed a partnership with Sanofi Genzyme to develop a treatment for transthyretin-mediated amyloidosis, a hereditary disease in Asia. In February 2013, it formed a partnership with The Medicines Company to develop a drug to treat a genetic form of high cholesterol.
In July 2013, during a Phase I trial Alnylam demonstrated statistically significant reduction of a protein called transthyretin, or TTR and demonstrated human efficacy with intravenous and subcutaneous modes of administration. In 2014, Sanofi Genzyme acquired a 12 percent stake in Alnylam and increased its rights to several of the company's drugs for $700 million. In a separate transaction Alnylam announced that it had purchased Merck & Co.'s Sirna Therapeutics, for $25 million cash and $150 million in stock. In 2015, the company had $41 million in revenue and a market cap of $5.2 billion.
In 2016, the company purchased land in Norton, Massachusetts to build a manufacturing facility.
In October 2016 the Phase III clinical trial of the company's lead product, revusiran, was halted due to increased deaths in the drug arm of the trial, and the company said it was terminating development of the compound.
On October 10, 2018, Alnylam appoints Margaret Hamburg to Board of Directors. Prior to this, from May 2009 to April 2015, she serves as Commissioner of the U.S. Food and Drug Administration (FDA).
In February 2020, Alnylam appointed former Sanofi CEO Olivier Brandicourt to its board of directors. In 2021, it was announced that Maraganore would step down as CEO, to be succeeded by the company's chief operating officer, Yvonne Greenstreet, on January 1, 2022.
In December 2021, Alnylam submitted a clinical trial authorisation (CTA) application to the Medicines and Healthcare Products Regulatory Agency in the United Kingdom to initiate a Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) for the treatment of Alzheimer's disease and cerebral amyloid angiopathy.
On December 22, 2021, Novartis announced that the US Food and Drug Administration (FDA) approved Leqvio (inclisiran), a small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol. Leqvio is indicated in the United States as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of LDL-C. The effect of Leqvio on cardiovascular morbidity and mortality is being explored in clinical trials currently underway. Novartis obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals.
Alnylam still does not earn money, but writes losses. The losses ("GAAP Operating Loss") from Alnylam were around $650 million in the late 2020. Alnylam expects to achieve net profits financially in 2022 or 2023.
In July 2023, Roche partnered with Alnylam Pharmaceuticals in a deal worth $2.8 billion for the development of a hypertension drug.
Products
In 2016, Alnylam Pharmaceuticals had 18 potential treatments in various development stages in genetic medicine, cardiometabolic disease and hepatic infectious disease.
Patisiran
In late 2016, the company's lead candidate in phase III studies was patisiran, a treatment targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR), in patients with the compromised nervous system condition of familial amyloidotic polyneuropathy (FAP).
In August 2018, with its commercial name Onpattro, patisiran received the U.S. regulatory approval to treat polyneuropathy in patients with hereditary ATTR amyloidosis.
FDA on patisiran for cardiomyopathy
In September 2023, the FDA raised doubts about the efficacy of patisiran for treating cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR-CM). The FDA's Cardiovascular and Renal Drugs Advisory Committee meeting is scheduled for September 13, 2023. Although the APOLLO-B study met key endpoints, the FDA questioned the clinical significance of the results particularly for patients not on background therapy with tafamidis. The FDA is seeking the committee's input on the clinical meaningfulness and patient populations for patisiran use potentially challenging Pfizer's tafamidis dominance in ATTR-CM treatment. A decision on Alnylam's application is expected by October 8, 2023. Patisiran was previously approved in 2018 for hereditary ATTR amyloidosis polyneuropathy, becoming the first RNA interference therapeutic approved by the FDA. The committee meeting chose to deny approval for the treatment of cardiomyopathy of ATTR amyloidosis with patisiran. Note that while patisiran was denied for the indication of cardiomyopathy, it remains an FDA approved treatment for polyneuropathy.
Vutrisiran
Alnylam went on to pursue the development of vutrisiran, which received FDA approval in 2022 and accounted for the majority of reported profit compared to patisiran/Onpattro in 2025.
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
ALNY Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
ALNY Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
ALNY Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
- Mocne kupno 8 21,6%
- Kup 21 56,8%
- Trzymaj 8 21,6%
- Sprzedaj 0 0,0%
- Mocna sprzedaż 0 0,0%
12-miesięczny cel cenowy
24 analityków · 2026-08-14Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
| Okres | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|
| 30 czerwca 2026 | $1.21 | $1.59 | -0.38% |
| 31 marca 2026 | $1.51 | $0.98 | 0.53% |
| 31 grudnia 2025 | $0.82 | $1.15 | -0.33% |
| 30 września 2025 | $2.11 | $0.76 | 1.3% |
| 30 czerwca 2025 | $-0.51 | $-0.73 | 0.22% |
| 31 marca 2025 | $-0.44 | $-1.03 | 0.59% |
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| ALNY | $52.64B | 170.7 | 65.2% | 8.5% | 60.4% | — |
| REGN | $106.21B | 18.6 | 0.99% | 31.4% | 14.7% | — |
| RVMD | — | — | — | — | — | — |
| NTRA | $32.00B | -150.7 | 35.9% | -9.0% | -14.1% | — |
| BIIB | $25.84B | 20.0 | 2.2% | 13.1% | 7.2% | — |
| INSM | $37.29B | -27.1 | 66.7% | -210.5% | -128.4% | — |
| INCY | $19.60B | 15.4 | 21.2% | 25.0% | 27.6% | — |
| MRNA | $11.62B | -4.1 | -39.9% | -145.2% | -31.3% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | — |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat 17
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.71B | $2.25B | $1.83B | $1.04B | $844M | $493M | $220M | $75M | $90M | $47M | · | · | |
| Cost of Revenue | $677M | $307M | $268M | $140M | $115M | $74M | $25M | $2M | $0 | · | · | · | |
| R&D Expense | $1.32B | $1.13B | $1.00B | $883M | $792M | $655M | $655M | $505M | $391M | $382M | $276M | $190M | |
| SG&A Expense | $1.21B | $976M | $796M | $771M | $621M | $588M | $479M | $382M | $199M | $89M | $61M | $45M | |
| Operating Expenses | $3.21B | $2.43B | $2.11B | $1.82B | $1.55B | $1.32B | $1.16B | $890M | $590M | $472M | $337M | $456M | |
| Operating Income | $502M | $-177M | $-282M | $-785M | $-709M | $-828M | $-939M | $-815M | $-500M | $-425M | $-296M | $-405M | |
| Interest Expense | · | · | $121M | $156M | $143M | $84M | $0 | $0 | · | · | · | · | |
| Interest Income | $111M | $122M | $96M | $25M | $2M | $12M | $33M | $29M | · | · | · | · | |
| Other Non-op | $5M | $-181M | $-126M | $-134M | $-2M | $57M | $21M | $25M | $-3M | $6M | $76.0K | $2M | |
| Pretax Income | $323M | $-377M | $-434M | $-1.13B | $-852M | $-856M | $-885M | $-761M | $-491M | $-410M | $-290M | $-401M | |
| Income Tax | $9M | $-99M | $7M | $4M | $680.0K | $3M | $863.0K | $823.0K | $0 | $0 | $0 | $-40M | |
| Net Income | $314M | $-278M | $-440M | $-1.13B | $-853M | $-858M | $-886M | $-761M | $-491M | $-410M | $-290M | $-360M | |
| EPS (Basic) | $2.39 | $-2.18 | $-3.52 | $-9.30 | $-7.20 | $-7.46 | $-8.11 | · | · | · | · | · | |
| EPS (Diluted) | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 | $-7.46 | $-8.11 | · | · | · | · | · | |
| Shares (Basic) | 131,004,000 | 127,651,000 | 124,906,000 | 121,689,000 | 118,451,000 | 114,986,000 | 109,264,000 | · | · | · | · | · | |
| Shares (Diluted) | 134,684,000 | 127,651,000 | 124,906,000 | 121,689,000 | 118,451,000 | 114,986,000 | 109,264,000 | · | · | · | · | · | |
| EBITDA | $557M | $-120M | $-228M | $-741M | $-661M | $-794M | $-922M | $-808M | $-487M | $-409M | $-277M | $-393M |
Bilans 23
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.66B | $966M | $813M | $866M | $820M | $497M | $547M | $420M | $645M | $194M | $181M | $75M | |
| Receivables | $778M | $405M | $328M | $238M | $199M | $102M | $43M | $19M | $34M | $23M | $8M | $40M | |
| Inventory | $83M | $79M | $89M | $129M | $86M | $75M | $56M | $24M | · | · | · | · | |
| Prepaid Expense | $282M | $117M | $126M | $133M | $88M | $63M | $80M | $74M | $40M | $22M | $17M | $10M | |
| Current Assets | $4.05B | $3.30B | $2.98B | $2.69B | $2.81B | $2.61B | $1.72B | $1.20B | $1.76B | $672M | $1.11B | $746M | |
| PP&E (Net) | $513M | $503M | $526M | $523M | $502M | $465M | $425M | $321M | $182M | $115M | $28M | $22M | |
| PP&E (Gross) | $836M | $773M | $749M | $697M | $642M | $569M | $501M | $400M | $249M | $176M | $79M | $68M | |
| Accum. Depreciation | $323M | $270M | $223M | $173M | $140M | $104M | $76M | $79M | $67M | $61M | $51M | $46M | |
| Other Non-current Assets | $59M | $65M | $62M | $66M | $60M | $45M | $18M | $9M | $4M | $2M | $1M | · | |
| Total Assets | $4.97B | $4.24B | $3.83B | $3.55B | $3.64B | $3.41B | $2.40B | $1.57B | $1.99B | $1.26B | $1.39B | $1.08B | |
| Accounts Payable | $116M | $88M | $56M | $98M | $73M | $52M | $50M | $60M | $28M | $54M | $17M | $15M | |
| Accrued Liabilities | $1.08B | $794M | $713M | $545M | $395M | $356M | $197M | $113M | $72M | $42M | $29M | $24M | |
| Current Liabilities | $1.47B | $1.19B | $968M | $768M | $696M | $585M | $353M | $179M | $144M | $132M | $62M | $95M | |
| Capital Leases | $225M | $230M | $243M | $261M | $281M | $293M | $276M | · | · | · | · | · | |
| Other Non-current Liabilities | $8M | $5M | $308M | $213M | $99M | $38M | $9M | $5M | $4M | $3M | $1M | · | |
| Total Liabilities | $4.18B | $4.17B | $4.05B | $3.70B | $3.06B | $2.39B | $956M | $273M | $228M | $343M | $122M | $143M | |
| Long-term Debt | · | · | · | · | $676M | $191M | · | · | · | · | · | · | |
| Common Stock | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $997.0K | $859.0K | $851.0K | $772.0K | |
| Retained Earnings | $-6.70B | $-7.29B | $-7.01B | $-6.57B | $-5.44B | $-4.59B | $-3.73B | $-2.84B | $-2.15B | $-1.66B | $-1.25B | $-957M | |
| AOCI | $-20M | $-35M | $-23M | $-45M | $-33M | $-44M | $-37M | $-33M | $-34M | $-33M | $4M | $49M | |
| Stockholders' Equity | $789M | $67M | $-221M | $-158M | $588M | $1.02B | $1.44B | $1.30B | $1.77B | $920M | $1.26B | $936M | |
| Liabilities + Equity | $4.97B | $4.24B | $3.83B | $3.55B | $3.64B | $3.41B | $2.40B | $1.57B | $1.99B | $1.26B | $1.39B | $1.08B | |
| Shares Outstanding | 132,376,000 | 129,294,000 | 125,794,000 | 123,925,000 | 120,182,000 | 116,427,000 | 112,188,000 | 101,177,000 | 99,667,000 | 85,941,000 | 85,090,968 | 77,202,753 |
Przepływy pieniężne 14
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $56M | $57M | $54M | $44M | $48M | $35M | $17M | $15M | $12M | $15M | $19M | $12M | |
| Stock-based Comp | $348M | $272M | $222M | $231M | $166M | $140M | $175M | $158M | $93M | $76M | $46M | $33M | |
| Deferred Tax | $-2M | $-107M | $-713.0K | $-1M | $-3M | $-3M | $-2M | $-788.0K | $0 | · | · | · | |
| Other Non-cash | $-191M | $48M | $269M | $316M | $614.0K | $72M | $418M | $35M | $2M | $12M | $36M | $150M | |
| Operating Cash Flow | $524M | $-8M | $104M | $-541M | $-642M | $-615M | $-278M | $-563M | $-383M | $-308M | $-189M | $-166M | |
| CapEx | $59M | $34M | $62M | $72M | $76M | $70M | $140M | $127M | $104M | $65M | $13M | $9M | |
| Investing Cash Flow | $436M | $-117M | $-336M | $169M | $-273M | $-436M | $-418M | $273M | $-290M | $143M | · | · | |
| Stock Issued | · | · | · | · | $0 | $0 | $382M | $0 | $1.14B | · | $496M | · | |
| Net Stock Activity | · | · | · | · | $0 | $0 | $382M | · | $1.14B | · | $496M | · | |
| Financing Cash Flow | $-305M | $294M | $172M | $426M | $1.25B | $995M | $823M | $65M | $1.12B | $178M | · | · | |
| Net Change in Cash | $690M | $154M | $-54M | $46M | $323M | $-51M | $127M | $-224M | $452M | $13M | $106M | $22M | |
| Taxes Paid | $15M | $14M | $6M | $3M | · | · | · | · | · | $111.0K | $66.0K | $-517.0K | |
| Free Cash Flow | $465M | $-43M | $42M | $-613M | $-718M | $-685M | $-419M | $-690M | $-487M | $-372M | $-202M | $-175M | |
| Levered FCF | · | · | $-81M | $-770M | $-861M | $-770M | · | · | · | · | · | · |
Rentowność 7
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 13.5% | -7.9% | -15.4% | -75.7% | -83.9% | -168.1% | -427.5% | -1087.6% | · | · | · | · | |
| Net Margin | 8.5% | -12.4% | -24.1% | -109.0% | -101.0% | -174.2% | -403.2% | -1016.6% | · | · | · | · | |
| Pretax Margin | 8.7% | -16.8% | -23.7% | -108.6% | -100.9% | -173.6% | -402.9% | -1015.5% | · | · | · | · | |
| EBITDA Margin | 15.0% | -5.3% | -12.5% | -71.4% | -78.3% | -161.0% | -419.7% | -1079.0% | · | · | · | · | |
| ROA | 6.8% | -6.9% | -11.9% | -31.5% | -24.2% | -29.6% | -44.6% | -42.7% | -30.1% | -31.0% | -23.5% | -48.0% | |
| ROE | 60.4% | -559.4% | 227.8% | 1001.6% | -126.9% | -76.9% | -58.2% | -54.8% | -36.5% | -37.5% | -26.4% | -59.7% | |
| ROIC | 61.7% | -194.3% | 129.9% | 498.0% | -120.6% | -81.8% | -65.4% | -62.6% | · | · | -23.4% | -38.9% |
Płynność i wypłacalność 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.8 | 2.8 | 3.1 | 3.5 | 4.0 | 4.5 | 4.9 | 6.7 | 12.2 | 5.1 | 17.8 | 7.8 | |
| Quick Ratio | 1.7 | 1.2 | 1.2 | 1.4 | 1.5 | 1.0 | 1.7 | 2.4 | 4.7 | 1.6 | 3.0 | 1.2 | |
| Interest Coverage | · | · | -2.3 | -5.0 | -5.0 | -9.8 | · | · | · | · | · | · |
Efektywność 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.6 | 0.5 | 0.3 | 0.2 | 0.2 | 0.1 | 0.0 | · | · | · | · | |
| Inventory Turnover | 8.4 | 3.7 | 2.5 | 1.3 | 1.4 | 1.2 | 0.6 | 0.1 | · | · | · | · | |
| Receivables Turnover | 6.3 | 6.1 | 6.5 | 4.8 | 5.6 | 6.8 | 7.1 | 2.8 | · | · | · | · |
Stopy Wzrostu 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 65.2% | 23.0% | 76.2% | 22.9% | 71.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 53.0% | 38.6% | 54.8% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 49.8% | · | · | · | · | · | · | · | · | · | · | · |
Wycena (TTM) 10
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.71B | $2.25B | $1.83B | $1.04B | $844M | $493M | $220M | $75M | $90M | $47M | $100M | $100M | |
| Net Income TTM | $314M | $-278M | $-440M | $-1.13B | $-853M | $-858M | $-886M | $-761M | $-491M | $-410M | $-290M | $-360M | |
| Market Cap | $52.64B | $30.42B | $24.08B | $29.45B | $20.38B | $15.13B | $12.92B | $7.38B | $12.66B | $3.22B | $8.01B | $7.49B | |
| P/E | 170.7 | -107.9 | -54.4 | -25.6 | -23.6 | -17.4 | -14.2 | · | · | · | · | · | |
| P/S | 14.2 | 13.5 | 13.2 | 28.4 | 24.1 | 30.7 | 58.8 | 98.5 | 140.8 | 68.2 | 80.3 | 75.1 | |
| P/B | 66.7 | 453.5 | -109.1 | -186.1 | 34.6 | 14.9 | 9.0 | 5.7 | 7.2 | 3.5 | 6.3 | 8.0 | |
| P / Tangible Book | 66.7 | 453.5 | · | · | 34.6 | 14.9 | · | · | · | · | · | · | |
| P / Cash Flow | 100.4 | -3660.3 | 231.2 | -54.4 | -31.8 | -24.6 | -46.4 | -13.1 | -33.1 | -10.5 | -42.4 | -45.2 | |
| P / FCF | 113.1 | -714.4 | 574.0 | -48.0 | -28.4 | -22.1 | -30.9 | -10.7 | -26.0 | -8.6 | -39.6 | -42.9 | |
| Earnings Yield | 0.59% | -0.93% | -1.8% | -3.9% | -4.2% | -5.7% | -7.0% | · | · | · | · | · |
Rachunek zysków i strat 17
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.29B | $1.17B | $1.10B | $1.25B | $774M | $594M | $593M | $501M | $660M | $494M | $440M | $751M | $319M | $319M | $335M | $264M | |
| Cost of Revenue | $298M | $208M | $268M | $197M | $142M | $70M | $103M | $82M | $67M | $55M | $72M | $79M | $75M | $41M | $46M | $37M | |
| R&D Expense | $413M | $365M | $372M | $359M | $324M | $265M | $300M | $271M | $294M | $261M | $272M | $253M | $249M | $231M | $262M | $245M | |
| SG&A Expense | $348M | $323M | $325M | $322M | $323M | $240M | $295M | $221M | $248M | $211M | $198M | $199M | $215M | $184M | $210M | $236M | |
| Operating Expenses | $1.06B | $899M | $965M | $881M | $790M | $576M | $698M | $578M | $611M | $538M | $556M | $537M | $549M | $469M | $524M | $522M | |
| Operating Income | $231M | $269M | $132M | $368M | $-16M | $18M | $-105M | $-77M | $49M | $-43M | $-116M | $214M | $-230M | $-150M | $-189M | $-258M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $35M | · | $31M | $30M | $29M | · | $41M | |
| Interest Income | $28M | $27M | $27M | $29M | $27M | $29M | $31M | $32M | $29M | $30M | $30M | $25M | $21M | $19M | $14M | $8M | |
| Other Non-op | $273.0K | $-4M | $135M | $-74M | $9M | $9M | $-81M | $-30M | $-56M | $-15M | $-20M | $-58M | $-35M | $-12M | $-3M | $-38M | |
| Pretax Income | $178M | $222M | $161M | $239M | $-41M | $-2M | $-194M | $-109M | $-11M | $-64M | $-138M | $151M | $-274M | $-172M | $-207M | $-406M | |
| Income Tax | $13M | $16M | $-25M | $-12M | $31M | $16M | $-110M | $3M | $6M | $2M | $183.0K | $3M | $2M | $2M | $472.0K | $-23.0K | |
| Net Income | $164M | $206M | $186M | $251M | $-72M | $-18M | $-84M | $-112M | $-17M | $-66M | $-138M | $148M | $-276M | $-174M | $-207M | $-406M | |
| EPS (Basic) | $1.23 | $1.55 | $1.43 | $1.91 | $-0.55 | $-0.14 | $-0.66 | $-0.87 | $-0.13 | $-0.52 | $-1.09 | $1.18 | $-2.21 | $-1.40 | $-1.69 | $-3.32 | |
| EPS (Diluted) | $1.21 | $1.51 | $1.44 | $1.84 | $-0.55 | $-0.14 | $-0.66 | $-0.87 | $-0.13 | $-0.52 | $-1.06 | $1.15 | $-2.21 | $-1.40 | $-1.69 | $-3.32 | |
| Shares (Basic) | 133,606,000 | 132,893,000 | -260,747,000 | 131,447,000 | 130,628,000 | 129,676,000 | -253,810,000 | 128,590,000 | 126,733,000 | 126,138,000 | -249,084,000 | 125,220,000 | 124,659,000 | 124,111,000 | -241,766,000 | 122,166,000 | |
| Shares (Diluted) | 138,281,000 | 138,226,000 | -262,968,000 | 137,348,000 | 130,628,000 | 129,676,000 | -253,810,000 | 128,590,000 | 126,733,000 | 126,138,000 | -255,201,000 | 131,337,000 | 124,659,000 | 124,111,000 | -241,766,000 | 122,166,000 | |
| EBITDA | $231M | $282M | · | $368M | $-16M | $32M | · | $-77M | $49M | $-30M | · | $214M | $-230M | $-136M | · | $-258M |
Bilans 22
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.71B | $1.71B | $1.66B | $1.49B | $1.11B | $1.02B | $966M | $1.10B | $968M | $682M | $813M | $1.03B | $658M | $672M | $866M | $1.07B | |
| Receivables | $913M | $884M | $778M | $965M | $567M | $418M | $405M | $354M | $309M | $321M | · | $325M | $221M | $219M | · | $185M | |
| Inventory | $97M | $84M | $83M | $75M | $72M | $66M | $79M | $76M | $84M | $94M | · | $96M | $100M | $132M | · | $115M | |
| Prepaid Expense | $302M | $242M | $282M | $188M | $147M | $152M | $117M | $145M | $155M | $202M | · | $158M | $145M | $119M | · | $126M | |
| Current Assets | $4.62B | $4.22B | $4.05B | $3.95B | $3.64B | $3.27B | $3.30B | $3.36B | $3.17B | $2.99B | · | $2.99B | $2.52B | $2.54B | · | $2.69B | |
| PP&E (Net) | $554M | $518M | $513M | $502M | $500M | $499M | $503M | $507M | $517M | $523M | · | $526M | $527M | $523M | · | $515M | |
| PP&E (Gross) | · | · | $836M | · | · | · | $773M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $323M | · | · | · | $270M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $65M | $64M | $59M | $56M | $57M | $74M | $65M | $78M | $72M | $67M | · | $75M | $93M | $63M | · | $61M | |
| Total Assets | $5.56B | $5.13B | $4.97B | $4.85B | $4.57B | $4.21B | $4.24B | $4.21B | $4.01B | $3.82B | · | $3.84B | $3.40B | $3.39B | · | $3.54B | |
| Accounts Payable | $108M | $127M | $116M | $118M | $102M | $97M | $88M | $71M | $74M | $78M | · | $74M | $60M | $62M | · | $41M | |
| Accrued Liabilities | $1.10B | $946M | $1.08B | $1.15B | $919M | $704M | $794M | $946M | $809M | $699M | · | $713M | $599M | $509M | · | $511M | |
| Current Liabilities | $1.51B | $1.35B | $1.47B | $1.56B | $1.30B | $1.08B | $1.19B | $1.22B | $1.06B | $942M | · | $950M | $789M | $673M | · | $773M | |
| Capital Leases | $210M | $218M | $225M | $223M | $224M | $230M | $230M | $236M | $239M | $238M | · | $248M | $253M | $259M | · | $266M | |
| Other Non-current Liabilities | $9M | $8M | $8M | $10M | $11M | $6M | $5M | $357M | $350M | $320M | · | $281M | $257M | $224M | · | $183M | |
| Total Liabilities | $4.20B | $4.05B | $4.18B | $4.62B | $4.32B | $4.10B | $4.17B | $4.17B | $4.01B | $4.04B | · | $4.00B | $3.81B | $3.65B | · | $3.60B | |
| Common Stock | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | · | $1M | $1M | $1M | · | $1M | |
| Retained Earnings | $-6.33B | $-6.50B | $-6.70B | $-7.16B | $-7.41B | $-7.35B | $-7.29B | $-7.20B | $-7.09B | $-7.08B | · | $-6.87B | $-7.02B | $-6.74B | · | $-6.36B | |
| AOCI | $-32M | $-25M | $-20M | $-22M | $-30M | $-38M | $-35M | $-25M | $-35M | $-27M | · | $-32M | $-37M | $-39M | · | $-44M | |
| Stockholders' Equity | $1.35B | $1.08B | $789M | $234M | $251M | $115M | $67M | $32M | $-3M | $-219M | $-221M | $-166M | $-408M | $-259M | $-158M | $-68M | |
| Liabilities + Equity | $5.56B | $5.13B | $4.97B | $4.85B | $4.57B | $4.21B | $4.24B | $4.21B | $4.01B | $3.82B | · | $3.84B | $3.40B | $3.39B | · | $3.54B | |
| Shares Outstanding | 133,734,000 | 133,444,000 | 132,376,000 | 131,791,000 | 130,977,000 | 130,311,000 | 129,294,000 | 128,841,000 | 128,021,000 | 126,463,000 | 125,794,000 | 125,454,000 | 124,901,000 | 124,241,000 | 123,925,000 | 122,991,000 |
Przepływy pieniężne 12
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $15M | $14M | $13M | $13M | $13M | $14M | $14M | $11M | |
| Stock-based Comp | $87M | $70M | $72M | $108M | $112M | $57M | $92M | $46M | $89M | $45M | $42M | $64M | $76M | $40M | $43M | $128M | |
| Deferred Tax | $3M | $9M | $-27M | $6M | $10M | $10M | $-107M | $-163.0K | $340.0K | $454.0K | · | · | · | · | · | · | |
| Other Non-cash | · | $-229M | · | · | · | $-142M | · | · | · | $-74M | · | · | · | $-46M | · | · | |
| Operating Cash Flow | $327M | $71M | $164M | $325M | $154M | $-120M | $-95M | $44M | $124M | $-82M | $-30M | $359M | $-59M | $-166M | $-132M | $-115M | |
| CapEx | $35M | $22M | $23M | $12M | $14M | $9M | $9M | $4M | $8M | $13M | $15M | $17M | $16M | $14M | $22M | $17M | |
| Investing Cash Flow | $-363M | $-26M | $-37M | $501M | $-141M | $114M | $-53M | $-30M | $34M | $-68M | $-241M | $-11M | $-9M | $-76M | $-140M | $314M | |
| Financing Cash Flow | $36M | $16M | $45M | $-448M | $54M | $46M | $31M | $103M | $131M | $29M | $39M | $33M | $53M | $46M | $63M | $297M | |
| Net Change in Cash | $-3M | $54M | $166M | $377M | $94M | $54M | $-134M | $131M | $286M | $-130M | $-220M | $375M | $-14M | $-194M | $-207M | $498M | |
| Taxes Paid | $12M | $2M | $13M | $1M | $-2M | $3M | · | $5M | $2M | $2M | · | · | · | · | · | · | |
| Free Cash Flow | · | $49M | · | · | · | $-127M | · | · | · | $-94M | · | · | · | $-180M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-131M | · | · | · | $-210M | · | · |
Rentowność 7
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 17.9% | 23.0% | · | 29.5% | -2.1% | 3.0% | · | -15.3% | 7.4% | -8.8% | · | 28.5% | -72.1% | -46.9% | · | -97.6% | |
| Net Margin | 12.7% | 17.6% | · | 20.1% | -8.6% | -9.7% | · | -22.3% | -2.6% | -13.3% | · | 19.7% | -86.6% | -54.5% | · | -153.6% | |
| Pretax Margin | 13.8% | 19.0% | · | 19.1% | -4.6% | -7.0% | · | -21.7% | -1.7% | -12.9% | · | 20.1% | -86.0% | -54.0% | · | -153.6% | |
| EBITDA Margin | 17.9% | 24.2% | · | 29.5% | -2.1% | 5.5% | · | -15.3% | 7.4% | -6.0% | · | 28.5% | -72.1% | -42.5% | · | -97.6% | |
| ROA | 3.2% | 4.4% | · | 5.5% | -1.6% | -1.4% | · | -2.8% | -0.46% | -1.8% | · | 4.0% | -8.2% | -5.1% | · | -11.6% | |
| ROE | 20.5% | 34.6% | · | 188.6% | -53.5% | 110.7% | · | 167.1% | 8.2% | 27.6% | · | -126.6% | 237.9% | -245.3% | · | -118.0% | |
| ROIC | 15.8% | 23.2% | · | 165.3% | -12.1% | 21.6% | · | -244.1% | -2397.3% | 20.5% | · | -126.4% | 56.7% | 58.4% | · | 381.5% |
Płynność i wypłacalność 3
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.1 | 3.1 | · | 2.5 | 2.8 | 3.0 | · | 2.7 | 3.0 | 3.2 | · | 3.1 | 3.2 | 3.8 | · | 3.5 | |
| Quick Ratio | 1.7 | 1.9 | · | 1.6 | 1.3 | 1.3 | · | 1.2 | 1.2 | 1.1 | · | 1.4 | 1.1 | 1.3 | · | 1.6 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -1.2 | · | 6.9 | -7.7 | -5.2 | · | -6.3 |
Efektywność 3
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.2 | · | 0.3 | 0.2 | 0.1 | · | 0.1 | 0.2 | 0.1 | · | 0.2 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 3.5 | 2.8 | · | 2.6 | 1.8 | 0.9 | · | 1.0 | 0.7 | 0.5 | · | 0.8 | 0.8 | 0.4 | · | 0.3 | |
| Receivables Turnover | 1.7 | 1.8 | · | 1.9 | 1.8 | 1.6 | · | 1.5 | 2.5 | 1.8 | · | 2.9 | 1.8 | 1.7 | · | 1.6 |
Wycena (TTM) 10
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.48B | $3.78B | · | $3.12B | $2.53B | $2.25B | · | $2.41B | $2.22B | $1.88B | · | $1.65B | $1.13B | $1.02B | · | $890M | |
| Net Income TTM | $549M | $373M | · | $55M | $-213M | $-213M | · | $-47M | $-211M | $-368M | · | $-708M | $-1.13B | $-1.10B | · | $-1.13B | |
| Market Cap | $40.26B | $44.15B | · | $60.10B | $42.71B | $35.19B | · | $35.44B | $31.11B | $18.90B | · | $22.22B | $23.72B | $24.89B | · | $24.62B | |
| P/E | 75.1 | 122.5 | · | 1425.0 | -197.6 | -162.7 | · | -743.3 | -142.1 | -50.2 | · | -30.6 | -20.6 | -22.2 | · | -21.5 | |
| P/S | 9.0 | 11.7 | · | 19.3 | 16.9 | 15.6 | · | 14.7 | 14.0 | 10.0 | · | 13.4 | 21.0 | 24.4 | · | 27.7 | |
| P/B | 29.7 | 41.1 | · | 256.9 | 170.4 | 304.8 | · | 1095.2 | -10143.2 | -86.2 | · | -134.0 | -58.1 | -96.0 | · | -364.0 | |
| P / Tangible Book | 29.7 | 41.1 | · | 256.9 | 170.4 | 304.8 | · | 1095.2 | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | 626.2 | · | · | · | -297.4 | · | · | · | -231.9 | · | · | · | -149.5 | · | · | |
| P / FCF | · | 907.2 | · | · | · | -276.4 | · | · | · | -200.0 | · | · | · | -138.0 | · | · | |
| Earnings Yield | 1.3% | 0.82% | · | 0.07% | -0.51% | -0.61% | · | -0.13% | -0.70% | -2.0% | · | -3.3% | -4.9% | -4.5% | · | -4.7% |
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
Rachunek zysków i strat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Przychody | $3.71B | $2.25B | $1.83B | $1.04B | $844M |
| Marża Operacyjna % | 13.5% | -7.9% | -15.4% | -75.7% | -83.9% |
| Zysk netto | $314M | $-278M | $-440M | $-1.13B | $-853M |
| Rozwodniony EPS | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 |
Bilans
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wskaźnik bieżący | 2.8 | 2.8 | 3.1 | 3.5 | 4.0 |
| Wskaźnik Szybkości | 1.7 | 1.2 | 1.2 | 1.4 | 1.5 |
Przepływy pieniężne
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $465M | $-43M | $42M | $-613M | $-718M |
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
Wybierz metryki, które są dla Ciebie ważne — kliknij ➕ obok dowolnego wiersza w Pełnych Fundamentach powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Właściciele instytucjonalni (13F) 877 emitentów · $27.1B łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 99 (-11 vs poprzedni kw.) | 77 (-68 vs poprzedni kw.) | 328 (+4 vs poprzedni kw.) | 259 (+4 vs poprzedni kw.) | +15.9M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| Capital World Investors | $3 354 715 611 | 11 144 846 | 12,36% | Akcje |
| FMR LLC | $3 108 157 652 | 10 325 076 | 11,45% | Akcje |
| Capital Research Global Investors | $2 935 115 324 | 9 750 699 | 10,81% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1 968 251 542 | 6 538 390 | 7,25% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $1 815 053 762 | 6 029 478 | 6,69% | Akcje |
| STATE STREET CORP | $1 070 369 060 | 3 555 689 | 3,94% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $686 853 582 | 2 288 725 | 2,53% | Akcje |
| NORGES BANK | $683 883 867 | 2 271 813 | 2,52% | Akcje |
| WELLINGTON MANAGEMENT GROUP LLP | $614 923 915 | 2 042 733 | 2,26% | Akcje |
| Dodge & Cox | $588 631 955 | 1 955 393 | 2,17% | Akcje |
| TWO SIGMA INVESTMENTS, LP | $564 713 315 | 1 875 937 | 2,08% | Akcje |
| AMERICAN CENTURY COMPANIES INC | $558 098 292 | 1 853 956 | 2,06% | Akcje |
| TWO SIGMA ADVISERS, LP | $450 362 484 | 1 132 560 | 1,66% | Akcje |
| Clearbridge Investments, LLC | $379 142 285 | 1 259 483 | 1,40% | Akcje |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $269 059 154 | 893 795 | 0,99% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $259 723 265 | 862 782 | 0,96% | Akcje |
| Deep Track Capital, LP | $248 349 750 | 825 000 | 0,91% | Akcje |
| Qube Research & Technologies Ltd | $240 437 176 | 798 715 | 0,89% | Akcje |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $219 642 021 | 729 635 | 0,81% | Akcje |
| BANK OF AMERICA CORP /DE/ | $176 408 397 | 586 016 | 0,65% | Akcje |
| LOOMIS SAYLES & CO L P | $170 456 431 | 566 244 | 0,63% | Akcje |
| BAILLIE GIFFORD & CO | $165 849 468 | 550 940 | 0,61% | Akcje |
| ROYAL BANK OF CANADA | $154 998 000 | 514 893 | 0,57% | Akcje |
| Polar Capital Holdings Plc | $145 322 534 | 482 751 | 0,54% | Akcje |
| Paradigm Biocapital Advisors LP | $144 494 400 | 480 000 | 0,53% | Akcje |
| D. E. Shaw & Co., Inc. | $129 533 209 | 430 300 | 0,48% | Opcja kupna |
| FIRST TRUST ADVISORS LP | $126 894 361 | 421 534 | 0,47% | Akcje |
| Swiss National Bank | $112 609 302 | 374 080 | 0,41% | Akcje |
| WELLS FARGO & COMPANY/MN | $111 381 100 | 370 000 | 0,41% | Opcja kupna |
| BlackRock, Inc. | $102 807 465 | 341 519 | 0,38% | Akcje |
| CANADA PENSION PLAN INVESTMENT BOARD | $100 618 073 | 334 246 | 0,37% | Akcje |
| Sumitomo Mitsui Trust Group, Inc. | $97 948 840 | 325 379 | 0,36% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $97 804 647 | 324 900 | 0,36% | Opcja kupna |
| Legal & General Group Plc | $97 467 493 | 323 780 | 0,36% | Akcje |
| MILLENNIUM MANAGEMENT LLC | $95 125 781 | 316 001 | 0,35% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $94 687 695 | 314 546 | 0,35% | Akcje |
| Candriam S.C.A. | $94 586 456 | 314 512 | 0,35% | Akcje |
| D. E. Shaw & Co., Inc. | $93 229 593 | 309 702 | 0,34% | Akcje |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $90 367 000 | 300 193 | 0,33% | Akcje |
| DEUTSCHE BANK AG\ | $89 849 026 | 298 472 | 0,33% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $88 641 294 | 294 460 | 0,33% | Akcje |
| Pictet Asset Management Holding SA | $83 257 214 | 278 613 | 0,31% | Akcje |
| BNP PARIBAS FINANCIAL MARKETS | $81 586 054 | 271 023 | 0,30% | Akcje |
| GILDER GAGNON HOWE & CO LLC | $80 992 374 | 269 051 | 0,30% | Akcje |
| CONGRESS ASSET MANAGEMENT CO | $79 983 972 | 265 701 | 0,29% | Akcje |
| VANGUARD ASSET MANAGEMENT, Ltd | $77 578 441 | 257 710 | 0,29% | Akcje |
| California Public Employees Retirement System | $76 477 575 | 254 053 | 0,28% | Akcje |
| WESTFIELD CAPITAL MANAGEMENT CO LP | $75 974 872 | 252 383 | 0,28% | Akcje |
| Korea Investment CORP | $74 553 090 | 247 660 | 0,27% | Akcje |
| Woodline Partners LP | $74 138 270 | 246 282 | 0,27% | Akcje |
| Squarepoint Ops LLC | $70 440 719 | 233 999 | 0,26% | Akcje |
| TD Asset Management Inc | $70 349 507 | 233 696 | 0,26% | Akcje |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $65 136 061 | 196 863 | 0,24% | Akcje |
| ROYAL LONDON ASSET MANAGEMENT LTD | $64 296 696 | 213 589 | 0,24% | Akcje |
| National Pension Service | $59 692 744 | 198 295 | 0,22% | Akcje |
| PINEBRIDGE INVESTMENTS LLC | $58 914 280 | 195 709 | 0,22% | Akcje |
| Robeco Institutional Asset Management B.V. | $56 618 929 | 188 084 | 0,21% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $53 824 164 | 178 800 | 0,20% | Opcja sprzedaży |
| VICTORY CAPITAL MANAGEMENT INC | $52 030 628 | 172 842 | 0,19% | Akcje |
| Mitsubishi UFJ Asset Management Co., Ltd. | $50 772 924 | 168 664 | 0,19% | Akcje |
| RHUMBLINE ADVISERS | $49 844 185 | 165 579 | 0,18% | Akcje |
| Life Cycle Investment Partners Ltd | $49 797 587 | 165 424 | 0,18% | Akcje |
| ANTIPODES PARTNERS Ltd | $49 228 339 | 163 533 | 0,18% | Akcje |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $47 228 883 | 157 223 | 0,17% | Akcje |
| CAPITAL FUND MANAGEMENT S.A. | $46 931 781 | 155 904 | 0,17% | Akcje |
| Assenagon Asset Management S.A. | $46 868 866 | 155 695 | 0,17% | Akcje |
| Vinva Investment Management Ltd | $45 487 381 | 154 972 | 0,17% | Akcje |
| JANUS HENDERSON GROUP PLC | $43 671 202 | 132 000 | 0,16% | Akcje |
| Hudson Bay Capital Management LP | $42 204 406 | 140 200 | 0,16% | Akcje |
| ENVESTNET ASSET MANAGEMENT INC | $41 059 106 | 136 395 | 0,15% | Akcje |
| ProShare Advisors LLC | $38 686 569 | 128 514 | 0,14% | Akcje |
| GOLDMAN SACHS GROUP INC | $37 029 700 | 123 010 | 0,14% | Akcje |
| LMR Partners LLP | $35 881 572 | 119 196 | 0,13% | Akcje |
| Man Group plc | $35 798 187 | 118 919 | 0,13% | Akcje |
| HSBC HOLDINGS PLC | $35 754 282 | 120 600 | 0,13% | Opcja sprzedaży |
| SCS Capital Management LLC | $34 783 715 | 115 549 | 0,13% | Akcje |
| AVIVA PLC | $34 477 568 | 114 532 | 0,13% | Akcje |
| Davern Capital Partners, LP | $34 041 978 | 113 085 | 0,13% | Akcje |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $33 770 750 | 112 184 | 0,12% | Akcje |
| Longaeva Partners L.P. | $33 191 869 | 110 261 | 0,12% | Akcje |
| 683 Capital Management, LLC | $32 360 725 | 107 500 | 0,12% | Opcja sprzedaży |
| MARSHALL WACE, LLP | $32 215 929 | 107 019 | 0,12% | Akcje |
| HighTower Advisors, LLC | $31 621 666 | 105 045 | 0,12% | Akcje |
| Bridgewater Associates, LP | $29 977 772 | 99 584 | 0,11% | Akcje |
| Prosight Management, LP | $29 525 022 | 98 080 | 0,11% | Akcje |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $28 956 123 | 96 408 | 0,11% | Akcje |
| Andra AP-fonden | $28 685 436 | 86 697 | 0,11% | Akcje |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $28 376 894 | 94 266 | 0,10% | Akcje |
| AMERIPRISE FINANCIAL INC | $28 191 159 | 93 649 | 0,10% | Akcje |
| BARCLAYS PLC | $27 979 234 | 92 945 | 0,10% | Akcje |
| TREMBLANT CAPITAL GROUP | $27 977 728 | 92 940 | 0,10% | Akcje |
| FIL Ltd | $27 652 616 | 91 860 | 0,10% | Akcje |
| Balyasny Asset Management L.P. | $26 945 195 | 89 510 | 0,10% | Akcje |
| Caisse de depot et placement du Quebec | $25 812 720 | 85 748 | 0,10% | Akcje |
| Mitsubishi UFJ Trust & Banking Corp | $24 911 136 | 82 753 | 0,09% | Akcje |
| RAYMOND JAMES FINANCIAL INC | $24 661 883 | 81 925 | 0,09% | Akcje |
| CITADEL ADVISORS LLC | $24 564 048 | 81 600 | 0,09% | Opcja kupna |
| VANGUARD GROUP INC | $24 356 460 | 61 251 | 0,09% | Akcje |
| NEOS Investment Management LLC | $23 562 822 | 78 274 | 0,09% | Akcje |
| JONES FINANCIAL COMPANIES LLLP | $23 444 213 | 80 462 | 0,09% | Akcje |
Insiderzy spółki 41 insiderów · 1 dyrektorzy generalni · 13 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Melissa Mclaughlin | Chief Human Resources Officer | 6 kwietnia 2026 S | 9 443 | 0 | 14 | $-1 274 343 |
| Colleen F Reitan | Dyrektor | 20 maja 2026 A | 1 446 | 0 | 0 | $0 |
| Charles Elliott Sigal | Dyrektor | 20 maja 2026 A | 1 446 | 0 | 0 | $0 |
| Stuart A Arbuckle | Dyrektor | 20 maja 2026 A | 671 | 0 | 0 | $0 |
| Olivier Brandicourt | Dyrektor | 20 maja 2026 A | 1 446 | 0 | 0 | $0 |
| Amy Schulman | Dyrektor | 20 maja 2026 A | 24 049 | 0 | 0 | $0 |
| Dennis A Ausiello | Dyrektor | 20 maja 2026 A | 1 582 | 0 | 0 | $0 |
| Margaret A Hamburg | Dyrektor | 20 maja 2026 A | 1 582 | 0 | 0 | $0 |
| KELLOGG PETER N | Dyrektor | 20 maja 2026 A | 1 446 | 0 | 0 | $0 |
| David E I Pyott | Dyrektor | 20 maja 2026 A | 1 582 | 0 | 0 | $0 |
| Victor J Dzau | Dyrektor | 21 czerwca 2012 A | — | 0 | 0 | $0 |
| Peter Barrett | Dyrektor | 1 czerwca 2006 A | 5 293 | 0 | 0 | $0 |
| John E Berriman | Dyrektor | 8 czerwca 2005 A | 2 475 | 0 | 0 | $0 |
| Christoph H Westphal | Dyrektor | 3 czerwca 2004 C | 2 409 970 | 0 | 0 | $0 |
| Sanofi | Posiadacz 10% | 31 maja 2017 P | 10 554 134 | 0 | 0 | $0 |
| ALNYLAM PHARMACEUTICALS, INC. | Posiadacz 10% | 23 lutego 2016 S | 4 896 716 | 0 | 0 | $0 |
| POLARIS VENTURE MANAGEMENT CO III LLC | Posiadacz 10% | 3 czerwca 2004 C | 2 409 970 | 0 | 0 | $0 |
| CHP II LP | Posiadacz 10% | 27 maja 2004 P | 232 500 | 0 | 0 | $0 |
| Akshay Vaishnaw | — | 10 sierpnia 2018 A | 395 | 0 | 0 | $0 |
| Barry E Greene | — | 10 sierpnia 2018 A | 9 030 | 0 | 0 | $0 |
| John Maraganore | — | 10 sierpnia 2018 A | 151 297 | 0 | 0 | $0 |
| SHARP PHILLIP A | — | 9 marca 2018 M | 140 795 | 0 | 0 | $0 |
| Michael Mason | — | 4 stycznia 2018 M | 0 | 0 | 0 | $0 |
| Laurie Keating | — | 29 grudnia 2017 M | 14 500 | 0 | 0 | $0 |
| Yvonne Greenstreet | — | 20 grudnia 2017 A | — | 0 | 0 | $0 |
| David-Alexandre C Gros | — | 20 grudnia 2016 A | — | 0 | 0 | $0 |
| SCHIMMEL PAUL | — | 19 listopada 2015 G | 306 996 | 0 | 0 | $0 |
| Marsha Fanucci | — | 1 czerwca 2015 A | 10 000 | 0 | 0 | $0 |
| Steven M Paul | — | 1 czerwca 2015 A | — | 0 | 0 | $0 |
| Michael W Bonney | — | 1 czerwca 2015 A | — | 0 | 0 | $0 |
| John K Clarke | — | 1 czerwca 2015 A | 2 091 868 | 0 | 0 | $0 |
| Kevin P Starr | — | 1 czerwca 2015 A | — | 0 | 0 | $0 |
| Laurence Reid | — | 19 maja 2014 M | 3 905 | 0 | 0 | $0 |
| Kenneth S Koblan | — | 8 grudnia 2010 A | — | 0 | 0 | $0 |
| Patricia L Allen | — | 8 grudnia 2010 A | 0 | 0 | 0 | $0 |
| James L Vincent | — | 18 czerwca 2010 M | 0 | 0 | 0 | $0 |
| Vicki L Sato | — | 2 czerwca 2010 A | — | 0 | 0 | $0 |
| Edward M Scolnick | — | 11 czerwca 2009 A | — | 0 | 0 | $0 |
| John A Schmidt Jr | — | 9 grudnia 2008 A | — | 0 | 0 | $0 |
| Vincent J Miles | — | 7 grudnia 2005 A | — | 0 | 0 | $0 |
| Abingworth Management LTD | — | 3 czerwca 2004 C | 18 745 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Aktywiści i właściciele 5%+ 2 akcje
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| CHP II, L.P. IRSN, CHP II Management LLC IRSN, John K. Clarke, Brandon H. Hull, John J. Park, Lisa M. Skeete Tatum ×2 zgłoszenia | 14 lutego 2007 | — | Pierwotne zgłoszenie | — | SEC |
| CHP II, L.P IRSN, CHP II Management LLC IRSN, John K. Clarke, Brandon H. Hull, John J. Park, Lisa M. Skeete Tatum | 15 lutego 2006 | — | Pierwotne zgłoszenie | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Posiadanie ETF-ów Posiadane przez 150 funduszy ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 3,25% | 53 807 SH | 8 sierpnia 2026 | Dziennie |
| NUMG · Nushares ETF Trust | 3,23% | 36 910 NS | 30 kwietnia 2026 | N-PORT |
| MID · AMERICAN CENTURY ETF TRUST | 3,19% | 10 523 NS | 31 maja 2026 | N-PORT |
| FMED · Fidelity Covington Trust | 2,79% | 3 791 NS | 31 maja 2026 | N-PORT |
| IBB · iShares Trust | 2,21% | 976 319 SH | 8 sierpnia 2026 | Dziennie |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 2,01% | 3 468 NS | 30 kwietnia 2026 | N-PORT |
| BIB · ProShares Trust | 2,01% | 4 904 NS | 31 maja 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 1,99% | 7 268 SH | 8 sierpnia 2026 | Dziennie |
| FDG · AMERICAN CENTURY ETF TRUST | 1,94% | 26 515 NS | 31 maja 2026 | N-PORT |
| JMID · Janus Detroit Street Trust | 1,40% | 824 NS | 30 kwietnia 2026 | N-PORT |
| CAML · Professionally Managed Portfolios | 1,29% | 15 623 NS | 30 kwietnia 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1,24% | 2 379 NS | 30 kwietnia 2026 | N-PORT |
| HRTS · Tema ETF Trust | 1,14% | 1 954 NS | 31 maja 2026 | N-PORT |
| MEDI · Harbor ETF Trust | 1,08% | 966 NS | 30 kwietnia 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,90% | 15 151 NS | 30 kwietnia 2026 | N-PORT |
| QQQE · Direxion Shares ETF Trust | 0,89% | 35 072 NS | 30 kwietnia 2026 | N-PORT |
| VOT · VANGUARD INDEX FUNDS | 0,88% | 1 022 888 SH | 8 sierpnia 2026 | Dziennie |
| IWP · iShares Trust | 0,82% | 770 414 SH | 8 sierpnia 2026 | Dziennie |
| JOET · Virtus ETF Trust II | 0,80% | 6 062 NS | 30 kwietnia 2026 | N-PORT |
| CGGR · Capital Group Growth ETF | 0,76% | 613 330 NS | 31 maja 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,66% | 60 901 NS | 30 kwietnia 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,59% | 398 693 SH | 8 sierpnia 2026 | Dziennie |
| FFLG · FIDELITY COVINGTON TRUST | 0,58% | 11 032 NS | 30 kwietnia 2026 | N-PORT |
| QNXT · iShares Trust | 0,54% | 699 SH | 8 sierpnia 2026 | Dziennie |
| USMV · iShares Trust | 0,47% | 527 555 SH | 8 sierpnia 2026 | Dziennie |
| IYH · iShares Trust | 0,47% | 79 894 SH | 8 sierpnia 2026 | Dziennie |
| VXF · VANGUARD INDEX FUNDS | 0,45% | 1 532 109 SH | 8 sierpnia 2026 | Dziennie |
| UPSD · ETF Series Solutions | 0,44% | 1 435 NS | 30 kwietnia 2026 | N-PORT |
| ILDR · First Trust Exchange-Traded Fund VI… | 0,43% | 4 118 NS | 31 maja 2026 | N-PORT |
| QFLR · Innovator ETFs Trust | 0,39% | 6 430 NS | 30 kwietnia 2026 | N-PORT |
| VO · VANGUARD INDEX FUNDS | 0,39% | 2 893 468 SH | 8 sierpnia 2026 | Dziennie |
| IMCG · iShares Trust | 0,38% | 72 243 SH | 8 sierpnia 2026 | Dziennie |
| FXH · First Trust Exchange-Traded AlphaDE… | 0,38% | 10 723 NS | 30 kwietnia 2026 | N-PORT |
| ESMV · iShares Trust | 0,35% | 128 SH | 8 sierpnia 2026 | Dziennie |
| SDG · iShares Trust | 0,33% | 2 658 SH | 8 sierpnia 2026 | Dziennie |
| SMIZ · Zacks Trust | 0,31% | 2 688 NS | 31 maja 2026 | N-PORT |
| ESLG · Strategy Shares | 0,31% | 196 NS | 30 kwietnia 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0,31% | 112 NS | 30 kwietnia 2026 | N-PORT |
| HEQQ · J.P. Morgan Exchange-Traded Fund Tr… | 0,30% | 305 NS | 30 kwietnia 2026 | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,28% | 94 NS | 31 maja 2026 | N-PORT |
| HQGO · Lattice Strategies Trust | 0,26% | 404 NS | 30 kwietnia 2026 | N-PORT |
| LRND · New York Life Investments ETF Trust | 0,24% | 2 252 NS | 30 kwietnia 2026 | N-PORT |
| ESUM · Strategy Shares | 0,23% | 1 141 NS | 30 kwietnia 2026 | N-PORT |
| FBCG · FIDELITY COVINGTON TRUST | 0,23% | 45 231 NS | 30 kwietnia 2026 | N-PORT |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 0,22% | 15 559 NS | 30 kwietnia 2026 | N-PORT |
| QCLR · Global X Funds | 0,21% | 27 NS | 30 kwietnia 2026 | N-PORT |
| QYLG · Global X Funds | 0,21% | 953 NS | 30 kwietnia 2026 | N-PORT |
| IWR · iShares Trust | 0,21% | 542 695 SH | 8 sierpnia 2026 | Dziennie |
| QRMI · Global X Funds | 0,21% | 108 NS | 30 kwietnia 2026 | N-PORT |
| QYLD · Global X Funds | 0,20% | 54 832 NS | 30 kwietnia 2026 | N-PORT |